Immunological consequences of thalidomide treatment in Sjogren's syndrome.
Immunological consequences of thalidomide treatment in Sjogren's syndrome.
复制标题
沙利度胺治疗干燥综合征的免疫学后果。
DOI：
10.1136/ard.2005.038406
复制
发表时间：
2006
影响因子：
27.4
通讯作者：
Wahl,SM
中科院分区：
文献类型：
--
作者：
Moutsopoulos,NM;Angelov,N;Sankar,V;Leakan,RA;Pillemer,S;Wahl,SM
目的：探讨沙利度胺治疗干燥综合征（Sjögren 'syndrome，SS）对机体免疫功能的影响。方法：测定患者和正常对照组（n = 7）治疗前后血浆细胞因子（肿瘤坏死因子α（TNFα）、白细胞介素6（IL 6））和可溶性白细胞介素2受体（sIL 2 R）水平。 通过流式细胞仪分析检测外周血单个核细胞中特定细胞群（T细胞、B细胞、单核细胞）的潜在变化，以及活化标志物（CD 25、HLA-DR）、共刺激分子（CD 40、CD 40 L）、TNF受体、趋化因子受体和粘附分子（L-选择素（L-sel））的表达。尽管如此，在4名接受治疗的患者中记录到细胞活化标志物的统计学显著变化。与健康对照组相比，治疗前患者组HLA-DR、TNFRI、CXCRI、CXCRII的表达均升高（p<0.05），治疗后患者组HLA-DR、TNFRI、CXCRI、CXCRII的表达均下调。B细胞的数量和表达的粘附分子-sel也下降与沙利度胺。结论：显着的变化，细胞活化的措施，检测沙利度胺治疗期间在这个有限的研究，进一步调查后，可能会提供深入了解沙利度胺的免疫调节途径。
Objective:To study the immunological consequences of systemic thalidomide treatment in patients with Sjögren’s syndrome.Methods:Cytokine (tumour necrosis factor α (TNFα), interleukin (IL) 6) and soluble receptor (sIL2R) levels were measured in patient and control plasma (n = 7), before and after thalidomide treatment. Peripheral blood mononuclear cells were examined by FACS analysis for potential changes in specific cell populations (T cells, B cells, monocytes), and for the expression of activation markers (CD25, HLA-DR), costimulatory molecules (CD40, CD40L), TNF receptors, chemokine receptors, and adhesion molecules (l-selectin (l-sel)).Results:Owing to adverse effects of thalidomide, the treatment interval was limited. None the less, statistically significant changes in markers of cell activation were recorded in the four treated patients. Before treatment, HLA-DR, TNFRI, CXCRI, and CXCRII were raised in the patients compared with healthy controls (p<0.05) and their expression was down regulated after treatment. B cell numbers and expression of the adhesion moleculel-sel also declined with thalidomide.Conclusion:Significant changes in measures of cell activation were detected during thalidomide treatment within this limited study, which upon further investigation may offer insight into the underlying immunoregulatory pathways of thalidomide.